Golino P, Buja L M, Yao S K, McNatt J, Willerson J T
Department of Internal Medicine (Cardiology Division), University of Texas Southwestern Medical Center, Dallas.
J Am Coll Cardiol. 1990 Mar 1;15(3):718-26. doi: 10.1016/0735-1097(90)90652-6.
This study was designed to test the efficacy of nitroglycerin and diltiazem in inhibiting in vivo platelet aggregation and reducing platelet-mediated vasoconstriction in a canine model of coronary artery stenosis and endothelial injury. Coronary artery diameter was measured in vivo by means of ultrasonic crystals sutured on the left anterior descending coronary artery (LAD) immediately distal to an external constrictor (LAD1), 1 cm below (LAD2), and on the left circumflex coronary artery. Coronary diameter was continuously measured before, during cyclic flow variations (progressive declines in blood flow followed by sudden restorations of flow due to recurrent intracoronary platelet aggregation), during cyclic flow variations and intravenous infusion of nitroglycerin (5 micrograms/kg per min) or diltiazem (15 micrograms/kg per min), and after cyclic flow variations were abolished by administration of LY53857, a serotonin receptor antagonist (n = 7), or SQ29548, a thromboxane A2 receptor antagonist (n = 7). During control cyclic flow variations, at the nadir of coronary flow (6% to 11% of the nonstenosed values), LAD1 cross-sectional area decreased by 43 +/- 8% and 44 +/- 3% in the two groups of dogs subsequently treated with LY53857 and SQ29548, respectively. Neither nitroglycerin nor diltiazem caused changes in cyclic flow variation frequency or severity. Furthermore, neither drug significantly reduced the vasoconstriction associated with cyclic flow variations, whereas they significantly increased circumflex artery cross-sectional area. In contrast, LY53857 and SQ29548 were very effective in abolishing cyclic flow variations and the coronary vasoconstriction related to them. Five additional dogs received an intracoronary infusion of nitroglycerin (21 +/- 5 micrograms/kg per min) and later diltiazem (15 micrograms/kg per min).(ABSTRACT TRUNCATED AT 250 WORDS)
本研究旨在测试硝酸甘油和地尔硫䓬在抑制犬冠状动脉狭窄和内皮损伤模型体内血小板聚集及减少血小板介导的血管收缩方面的疗效。通过将超声晶体缝合在左冠状动脉前降支(LAD)紧邻外部缩窄器(LAD1)的远心端、下方1厘米处(LAD2)以及左旋冠状动脉上,在体内测量冠状动脉直径。在循环血流变化(由于冠状动脉内反复血小板聚集导致血流逐渐下降随后突然恢复)之前、期间、循环血流变化期间及静脉输注硝酸甘油(5微克/千克每分钟)或地尔硫䓬(15微克/千克每分钟)时,以及在给予5-羟色胺受体拮抗剂LY53857(n = 7)或血栓素A2受体拮抗剂SQ29548(n = 7)消除循环血流变化后,连续测量冠状动脉直径。在对照循环血流变化期间,在冠状动脉血流最低点(非狭窄值的6%至11%),随后分别用LY53857和SQ29548治疗的两组犬中,LAD1横截面积分别减少43±8%和44±3%。硝酸甘油和地尔硫䓬均未引起循环血流变化频率或严重程度的改变。此外,两种药物均未显著降低与循环血流变化相关的血管收缩,而它们显著增加了左旋冠状动脉横截面积。相比之下,LY53857和SQ29548在消除循环血流变化及与之相关的冠状动脉血管收缩方面非常有效。另外5只犬接受冠状动脉内输注硝酸甘油(21±5微克/千克每分钟),随后输注地尔硫䓬(15微克/千克每分钟)。(摘要截取自250字)